Claim Ownership


Author: MassDevice

Subscribed: 10Played: 34


The DeviceTalks Podcast series delivers news, insights and commentary from Medtech industry leaders. From our DeviceTalks Weekly to DeviceTalks Keynotes, our podcasts will bring inspiration and road maps for professional growth to medtech professionals.
84 Episodes
INNOVATION & FINANCE: Is the traditional road show dead? Leslie Trigg, CEO of Outset Medical, fresh off taking the renal care company public, says despite initially grieving her inability to meet investors in person, she agrees that Zoom meetings gave her all the insights she needed to stage a successful IPO. In fact, she says the video calls might have even engendered a deeper understanding between executives and investors. Trigg also explains how Outset came to broaden its overall mission to create an enterprise system for dialysis. NEW TOOLS & TECHNOLOGY: The doctor will see you now … from 3,000 miles away. Doug Teany, COO of Corindus Vascular Robotics, says the company’s Corpath interventional robotic system will save lives and money by shortening the distance between critical patients and capable care. Using the emerging 5G network, Corindus is moving toward a future where interventionalists can treat patients in different area codes, time zones and countries. The company is profiled in a 5G documentary called “Speed of Thought.” Check it out on Amazon Prime and other channels. Finally, the week wouldn't be complete with Chris Newmarker, executive editor of MassDevice, revealing this week’s #Newmarkersnewsmakers featuring news from Hologic, Varian, Smith & Nephew, and Outset Medical.
MANUFACTURING & SOURCING: This week, the DeviceTalks Weekly Podcast explores the potential of single-use endoscopes. Co-host Tom Salemi interviews leaders from the leaders – Ambu and Boston Scientific. First, Ambu CEO Juan Jose Gonzalez and Stephen Block, president of Ambu US, introduce us to one of medtech’s fastest growing companies. Ambu is moving into the single-use market with a less expensive alternative to those offered by larger rival Boston Scientific. We’ll find how Gonzalez and Block view the opportunity. In our second interview, we dig into the EXALT offering with Boston Scientific’s CMO Brian Dunkin, MD and Dave Pierce, EVP and President MedSurg. After a slow start due to COVID-19 shutdowns, Boston Scientific is putting the pedal to the metal by leveraging its extensive reach and might. Executives from both companies share why they can't see the ceiling to the potential of this technology. MassDevice's Executive Editor Chris Newmarker will reveal this week’s #NewmarkersNewsmakers including Bardy Diagnostics, Kevin Hykes, COVID-19 Vaccine makers, Theranica, Joe Biden, Donald Trump and Theranos founder Elizabeth Holmes.
Our line up in Episode 25 of the DeviceTalks Weekly Podcast INNOVATION & FINANCE – Managing Partner Karen Long says COVID-19 isn’t slowing down KCK Group, which closed on two major investments this summer. Long will be speaking on our first DeviceTalks Tuesday’s “Raising Capital in the Zoom Age.” Go to REGULATORY & REIMBURSEMENT – Gail Daubert, founding partner at 4Front Strategies walks us through the proposed CMS rule to pay for innovative breakthrough technologies. Daubert suggests industry leaders offer their feedback on the proposed rule. For information on submitting feed back go to NEWMARKER’S NEWSMAKERS – Chris Newmarker, executive editor of life sciences at MassDevice, reports on the five biggest Medtech newsmakers. Items involve Medtronic, IBM, Elon Musk, and CMS.
In this week’s DeviceTalks Weekly Podcast, Kaila Krum, managing director at Truist Securities, explains why Medtronic is talking tough about finding new growth. Can the medtech giant pull off CEO Geoff Martha’s pledge to `Go Big or Go Home.” Juan-Pablo Mas, partner at Action Potential Venture Capital, lends insights on his group’s commitment to EXO (pronounced echo), a maker of a portable ultrasound imaging device that might have somewhat unforeseen therapeutic applications. He also shares his hopes for LatinxVC, a non-profit creating opportunities in venture capital. Senior Editor Danielle Kirsh and Assistant Editor Sean Whooley pinch hit for Chris Newmarker. Kirsh lays out her plans for this year’s Women in Medtech issue and Whooley walks us through this week’s Top 5 stories (aka Newmarker’s Newsmakers.) Medtronic, Abbott, Boston Scientific, Pelvital, and iRhythm all make the list. But who is number 1?
In this week’s episode of the DeviceTalks Weekly podcast, co-hosts Tom Salemi, editorial director of DeviceTalks, and Chris Newmarker, executive editor of life sciences, review this week's Top 5 medtech stories, aka “Newmarker’s Newsmakers,” with news coming from CureVac, Avail Medsystems, ClearMask, Thermo Fisher and Bayer. We also hear from two executives from Fractyl Laboratories — CEO Dr. Harith Rajagopalan and CFO Lisa Davidson — about its recent $55 million Series E round of financing and the strides they're making in developing a device to treat diabetes. In a second interview, Cala Health CEO Renee Ryan gives us an update on the Cala Trio’s clinical success and how the start-up is working through COVID-19. Finally, Chris and Tom hint at an upcoming event for the DTW community.
DeviceTalks Weekly: Ep. 22 – This week’s episode of DeviceTalks Weekly is brought to you by the later V, as in Vizient and Vicarious Surgical. Bharat Sundaram, COO and president of Vizient, will share how the healthcare supplier is strengthening the supply of PPE for hospitals. He'll also reveal when the company expects to see US hospitals running at pre-Covid levels. Hint, it'll be a while. Adam Sachs, CEO of Vicarious Surgical, tells us how the company will put a new round of capital from high-powered investors to work in developing to develop a surgical system employing robotic and virtual reality technologies. How does the start-up expect to compete with the established leaders in the robotics space? Co-host Chris Newmarker, executive editor, life sciences, will walk us through the five biggest newsmakers on the MassDevice site. Number one may surprise you, but given the time, perhaps it shouldn’t.
Ten ways medtech is finding its footing during the pandemic When COVID19 set upon the US in March, medtech executives had a month at most to tell Wall Street analysts how the pandemic had hit the industry’s largest companies. We heard about short-term hits in revenues, procedures and employee headcounts, but uncertainty clearly ruled the day. Over the past weeks, medtech executives from several leading companies reported back to analysts with a full quarter under their belt. To be sure, no one can claim to hold a full grasp on this crisis, but a survey of the calls reveals several observations worth pointing out . In this podcast, we’ll list our Top 10. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players. It’s available on Apple Podcasts, Spotify and other podcast channels.
In this week’s podcast, two executives from Thrive Earlier Detection explain how the “turbo-charged” diagnostics company intends to upend how, when and where cancer is diagnosed. Isaac Kinde, MD, PhD, co-founder and head of research and innovation, walks us through the company’s CancerSEEK test and how the company is marrying new technology with an innovative clinical approach. Meanwhile, Isaac Ro, tells host Tom Salemi how the company closed on $257 million (hint: lots of Zoom) and why he left a career on Wall Street to join this innovative start-up. Chris Newmarker, executive editor of life sciences at MassDevice, also counts down on the biggest newsmakers in this week’s MassDevice. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players. It’s available on Apple Podcasts, Spotify and other podcast channels.
In this week’s podcast, we talk with Holly Logue, general counsel at Drawbridge Health, about the OneDraw, an innovative new tool that might upend the collecting, storage and testing of blood. Logue, a panelist in the upcoming DeviceTalks Tuesdays sponsored by Finnegan, will explain how her past work on Capitol Hill is helping this Silicon Valley company’s plans. Meanwhile, we speak with Daveen Chopra, corporate vice president of surgical structural heart at Edwards Lifesciences, about that company’s commitment to treating the most serious cardiac patients. The company recently won FDA approval for its Konect Resilia aortic valve conduit, a vital new tool in helping heart patients, including many requiring emergency story. Co-costs Tom Salemi, editorial director of DeviceTalks, and Chris Newmarker, executive editor of life sciences at MassDevice, review the five biggest news stories of the week. We'll talk about Abbott, Becton Dickinson, Boston Scientific, Edwards Lifesciences, and Theranos. Number one may surprise you.
For years, medtech companies have known connectivity was good for them, but the promise of data streaming through devices didn't match the reality. COVID-19 changed that, creating an opportunity for device companies with connectivity plans in place. In this episode, we speak with Dr. David Hayes, CMO of Biotronik, about that companies success in connecting cardiology patients. Meanwhile, Bill Betten of S3 Connected Health explains what device companies must do to prepare for medtech's next age. We also review the week's top news involving Medtronic, Johnson & Johnson, Abbott, Edwards, and Smith+Nephew
DeviceTalks Weekly: Ep. 17 – In this week’s episode of DeviceTalks Weekly, we follow up with Nadim Yared, CEO of CVRx, the guest of last week’s episode, to catch up on how the medtech executives is managing during the pandemic. Yared also shares some far-reaching views on what the medtech industry needs to work toward to improve diversity in its workforce and provide equality for society. We also visit with Mira Sahney, CEO of Hyalex Orthopaedics, one of medtech’s most interesting startups; Hyalex was identified as a notable startup in the recent report in Medical Design and Outsourcing. In this interview, Sahney reveals Hyalex’ origins, the state of its potential cartilage replacement product, and why start-ups have a natural advantage operating in a pandemic. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
Nadim Yared, CEO of CVRx This week, CVRX reported positive six-month trial results for its Barostim Neo, an FDA-approved treatment for heart failure. The results follow years of close work between the agency and CVRx, one of the more ambitious startups in medtech. CVRx is targeting a huge clinical need with novel neuromodulation technology. In this week’s DeviceTalks Weekly podcast, CEO Nadim Yared walks us through the negotiations the company went through with the FDA to get to this point. Yared, the prior chairman of the industry group AdvaMed, also shares the story of his career, which started early on when he secured a job at GE even before graduating college. In this talk, Yared speaks to several issues including: The power of confidence and the dangers of overconfidence when building a career. -How he decided to take the job at CVRx (and why he didn’t initially want to talk about the job with a recruiter.) -What CVRx learned from other successes and failures in renal denervation. -Why the company is betting big on heart failure, but doesn't have a Chief Medical Officer. -Whether or not his role as chairman at AdvaMed impacted his work at CVRx. -Can medtechs generate good returns after raising hundreds of millions in capital? This conversation took place prior to the emergence of COVID-19, so DTW host Tom Salemi visited again with Yared more recently. We’ll play that interview in next week’s episode of DeviceTalks Weekly. If you’re looking for more medtech discussions, register now for DeviceTalks Weekly at Subscribe to he podcast. Don’t miss an episode!
DeviceTalks Weekly: Ep. 15 – Why FDA put the pedal to the metal for radar and hummingbirds. And why medtech needs Google. In this week’s episode of DeviceTalks Weekly, co-hosts Chris Newmarker and Tom Salemi dig into the recent successes by start-ups Circadia Health and Perceptis Medical, which both saw expedited approval from the FDA due to the pandemic. We also unveil the 20 medical device companies you need to know. Circadia CEO Fares Siddiqui discusses the quick approval that came for his company’s C100 system that uses radar to monitor respiratory function. Preceptis Medical CEO Steve Anderson, meanwhile, explains why the agency – and he hopes payers – want to see his company’s ear-tube implanting system on the market. We also visit with Heidi Dohse, Sr. Program Manager at Google’s Cloud Healthcare & Life Sciences organization, who will be leading the upcoming DeviceTalks Tuesday’s discussion about how medtech devices can use data to better serve its sickest patients. Dohse partners with physicians and researchers around the world to provide insights regarding the patient experience and ideas for engagement. She travels globally educating audiences on digital health, data and healthcare. On Tuesday, she’ll discuss. • How do we weigh “patient lifestyles” vs. “therapy/product” lifecycles”? • What impact will connected devices and apps have on patient outcomes? • How can data help improve and even transform the patient experience? • Speaker: Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company – and the industry group AdvaMed – has been working  to increase diversity of its workforce, particularly in senior and sales positions. Lobo is serving a two-year term as chairman of AdvaMed. In this interview, Lobo speaks specifically to how Stryker is tracking progress, where it has come up short, and how it’s working to help workers identify their own biases. Lobo also says Stryker is poised to regain momentum after the pandemic. Next, Kevin Sayer, executive chairman, CEO and president of Dexcom, says the company’s continuous glucose monitors are finding a home in hospitals as they help monitor the health of COVID-19 patients. Sayer says the company’s monitors have helped keep patients, especially diabetics, off ventilators and allowed them to get discharged more quickly. What’s next for Dexcom? “We think this is an important market for us, not just COVID-wise,” Sayer says. Finally, Raj Denhoy, equity research analyst at Jefferies, breaks down private equity group Blackstone’s investment in Medtronic’s diabetes line. Why would the medtech giant take outside money? Is this something we’ll see more of in medtech? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
DeviceTalks Weekly: Ep. 13 –  Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health. Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor. We ask Ryan about her move into medtech investing from investment banking as well as the  “secret power” that helped her succeed as an investor and an executive. We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor. The interview was conducted in February. What role will tech companies play in medtech’s future? Did Verb Surgical meet her expectations? As CEO how do you manage investor syndicates with multiple corporate investors? Can Cala secure reimbursement and create a new market for tremors? What grade did she skip as a child? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
In this week’s DeviceTalks Weekly podcast, we attempt to deliver heartfelt and hard won advice in a sort of commencement address by Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer of Edwards Lifesciences. Dr. Brinton sits down with host Tom Salemi to share his path into Medtech. Brinton shares great advice for anyone looking for a new career or opportunity in medtech. NOTE: This conversation was recorded in March, prior to the full impact of the COVID-19 pandemic.
DeviceTalks Weekly: Ep. 11 – Medtronic is buckling up and ready to buy In this week’s episode of DeviceTalks Weekly, we dip into Medtronic’s quarterly call to hear why company executives feel the medtech sector is already rebounding. The global giant also intends to start using its vast cash reserves to bolster its bottomline through M&A. We’ll also talk with Jeff Champagne of MPR about medtech’s need for speed. He’ll be leading a discussion on this subject and more on the upcoming DeviceTalks Tuesdays. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
DeviceTalks Weekly: Ep. 10 – How do medtech investors, CEOS manage portfolio companies going forward? In this week’s episode of DeviceTalks Weekly, we talk with two successful starters of medtech companies about how they’re building and maintaining their medtech portfolios during this pandemic landscape. Our guests this week are… • Justin Klein, MD, managing partner, Vensana Capital • Duke Rohlen, chairman, Ajax Health Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions. Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS (acquired). Rohlen, who leads a holdings company backed by private equity giant KKR, previously served as chairman and CEO of EPIX, Co-founder, Chairman and CEO of Spirox, Inc (sold to Entellus Medical) and co-founder and CEO of CV Ingenuity. He was also president of Fox Hollow before it was acquired by EV3. In this podcast we’ll learn how VCs are looking at investment opportunities in this market • Are they making new investments? • What impact is this having on valuation? • Do VCs give stronger consideration to new concerns like supply chain? • When will they get clinical trials up and running? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
In this week’s episode of DeviceTalks Weekly, Tom Salemi speaks with two executive recruiters about what they see in the medtech market. Over the past month, we’ve seen several medtech companies – big and small – cutting jobs and reducing hours but what does this mean long-term. In this podcast we’ll identify a few companies that are hiring, but we’ll talk in-depth with the recruiters about… • How bad is the current market? • What’s the likelihood for recovery? • What skills are in greater demand? • What can people do to strengthen their hand? Guests are: • David L. Vied, global sector leader, Global Sector Leader, Medical Devices and Diagnostics, Korn Ferry • Giovanni Lauricella, vice president, medtech practice-lead, The Mullings Group Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
DeviceTalks Weekly: Ep. 8 – AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 venture capital investment data In this week’s episode of DeviceTalks Weekly, Scott Whitaker, CEO of AdvaMed, shares concerns he had over how the federal government would work with the medtech industry during the pandemic crisis. Does he feel the medtech industry was treated fairly? How does he see the federal government and medtech industry working together in the future? He answers those questions and more. In our second interview, Jonathan Norris, managing director of Silicon Valley Bank, shares first-quarter data for medtech venture investments. The results might surprise you. Guests are: • Scott Whitaker, CEO, AdvaMed • Jonathan Norris, managing director, Silicon Valley bank Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
Download from Google Play
Download from App Store